Table 4.
Effect of 8-week treatment using BE capsules on the metabolic parameters.
| Placebo (n = 15) |
Treated (n = 16) |
|||||
|---|---|---|---|---|---|---|
| Parameter | Baseline | 8 weeks | Baseline | 8 weeks | pa | pb |
| Postprandial plasma glucose (mmol/l) | 15.2 ± 4.1 | 15.6 ± 3.7 | 16.0 ± 2.4 | 11.7 ± 1.01 | ns | 0.003 |
| Fasting plasma glucose (mmol/l) | 8.2 ± 0.6 | 8.5 ± 1.1 | 8.7 ± 1.9 | 7.8 ± 0.9 | 0.05 | 0.04 |
| Plasma – triglyceride (mg/dl) | 181.7 ± 2.9 | 179.1 ± 8.5 | 172.4 ± 4.3 | 156.8 ± 5.1 | 0.05 | 0.003 |
| Plasma – total cholesterol (mg/dl) | 216.9 ± 11 | 217.1 ± 8.1 | 211.5 ± 6.8 | 184.5 ± 3.9 | 0.03 | 0.002 |
| Plasma – HDL (mg/dl) | 31.9 ± 8.6 | 32.8 ± 7.9 | 32.7 ± 2.9 | 46.6 ± 7.0 | 0.03 | 0.004 |
| Plasma – LDL (mg/dl) | 144.5 ± 5.2 | 140.1 ± 6.8 | 138.6 ± 11.1 | 109.0 ± 5.4 | ns | 0.003 |
| LDL:HDL | 4.5 | 4.27 | 4.2 | 2.33 | ||
| Serum insulin (mU/l) | 11 ± 2.3 | 11 ± 4.6 | 10 ± 1.2 | 10 ± 1.7 | ns | ns |
| Serum C-peptide (pmol/l) | 476 ± 58.9 | 482 ± 63.1 | 493 ± 71.3 | 495 ± 69.2 | ns | ns |
| Plasma – ALT (U/l) | 39.1 ± 3.1 | 36.9 ± 4.6 | 36.4 ± 8.7 | 20.87 ± 8.7 | 0.05 | 0.004 |
| Plasma – AST (U/l) | 27.5 ± 9.0 | 28.1 ± 3.2 | 31.4 ± 10.1 | 17.8 ± 8.7 | 0.03 | 0.004 |
| Plasma creatinine (μ mol/l) | 0.71 ± 0.06 | 0.69 ± 0.01 | 0.88 ± 3.4 | 0.90 ± 8.7 | 0.01 | ns |
| Plasma urea (mg/l) | 18.3 ± 1.7 | 17.5 ± 1.8 | 15.5 ± 2.6 | 16.93 ± 8.7 | 0.01 | ns |
Data are mean ± standard deviation.
ns: not statistically significant.
pa: within-group statistical significance calculated for the data; pb: statistical significance from the placebo group.
Values of p < 0.05 were considered significant.